# Efficacy and Safety of RC28-E Versus Aflibercept

> **NCT05727397** · PHASE3 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 432 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** RC28-E
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05727397
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-14
- **Primary completion:** 2025-11-29
- **Final completion:** 2025-12-29
- **Target enrollment:** 432 (ESTIMATED)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05727397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05727397, "Efficacy and Safety of RC28-E Versus Aflibercept". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05727397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*